Forward P/S Multiple: CytoSorbents Corp (CTSO)
Efficient distribution of blood purification systems in Europe and the US ensures a high operating margin for Cytosorbents (CTSO). This forecast P/S chart for Cytosorbents (CTSO) visualizes the current market valuation, where the value 0.50 represents the current metric. This facilitates global dominance in sepsis therapy through the implementation of CytoSorb cartridges, which, amid growing demand in intensive care units, expands the client base worldwide.
Summary analytical data breakdowns for cytosorbents.com (CTSO)
- market price and analyst price targets:
- company stock exchange capitalization indicators:
- issuer book value statistics:
- debt and liquidity data:
Total Debt to Capital Cytosorbents|CTSO - Long-Term Debt to Equity Ratio|Short-Term Debt to Capital CytoSorbents Corporation|CTSO - Company Aggregate Debts|Debt to Book Capitalization Ratio CytoSorbents Corporation|CTSO - Company Long-Term Debt|Company Current Liabilities Cytosorbents|Quick Ratio cytosorbents.com
- financial results and valuation multiples details:
CTSO - Company Net Income|Expected Profit Cytosorbents|CTSO - Market Cap to Net Income Ratio|Projected Price to Earnings CytoSorbents Corporation|CTSO - PEG Multiple|EV/EBITDA Multiple CytoSorbents Corporation|CTSO - Operating income before deduction of amortization|Earnings per share for the last twelve months Cytosorbents|CTSO - Earnings per one share for the last 12 months|Year-over-year earnings per share growth for the last twelve months cytosorbents.com|CTSO - Net earnings per share growth this year|Earnings growth forecast for next year Cytosorbents
- sales and revenue indicators:
Fundamental company analysis:CTSO (CytoSorbents Corp.)
Forward P/S compares current market capitalization with expected sales volume, allowing investors to determine the extent to which an asset's value is overpriced relative to future cash flows. The forward price-to-sales analysis for Cytosorbents (CTSO) demonstrates how European revenue offsets the costs of US development, confirming the fundamental resilience of the business during a period of investment pressure.
Who Cytosorbents competes with
Price-to-Projected Revenue Ratio Dexcom DXCM|PEN - Forward Price-to-Revenue Multiple|Novanta Corp - Forward P/S Multiple|Market Cap to Future Revenue Ratio Haemonetics Company|INSP: Forward P/S Multiple|Market Cap to Projected Revenue PRCT|CNMD (CONMED) - Forward P/S Multiple|Pulse Biosciences Inc (PLSE) - Market Cap to Expected Sales Ratio|Forward P/S Multiple INMD|Forward Price-to-Revenue Multiple Picard Group PMI|Forward P/S Multiple SRDX (Surmodics, Inc.)|Forward P/S Multiple senseonics.com SENS|NPCE - Price-to-Projected Revenue Ratio|TCMD: Price-to-Projected Revenue Ratio|SNWV (SANUWAVE Health, Inc.) - Forward Price-to-Revenue Multiple|Outset Medical Corp - Forward Price to Sales|ELMD (SmartVest) - Forward P/S Multiple|Market Cap to Future Revenue Ratio lensar.com LNSR|Price-to-Projected Revenue Ratio AVITA Medical (RCEL)|profoundmedical.com (PROF) - Projected Price to Revenue|Baird Medical - Forward Price-to-Revenue Multiple|Forward P/S Multiple EDAP TMS SA EDAP|Bovie Medical - Forward P/S Multiple|Market Cap to Expected Sales Ratio IceCure Medical Ltd ICCM|pulmonx.com (LUNG) - Price-to-Projected Revenue Ratio|Future Price to Revenue TELA (TELA Bio)|Price-to-Projected Revenue Ratio Sensus Healthcare Corp|Forward Price-to-Revenue Multiple Zynex Corp (ZYXI)|Forward P/S Multiple ECOR|RBOT - Market Cap to Future Revenue Ratio|Price-to-Projected Revenue Ratio Inspira Technologies IINN|ICU: Market Cap to Projected Revenue|IRIX: Forward Price-to-Revenue Multiple|Intelligent Bio Solutions - Price to Expected Revenue Ratio|XAIR: Forward P/S Multiple|Forward Price-to-Revenue Multiple profusa.com|Forward Price-to-Revenue Multiple SSKN|Market Cap to Future Revenue Ratio glucotrack.com GCTK|Forward Price-to-Revenue Multiple NAOV (NanoVibronix)|Price to Expected Revenue Ratio VERO|Price-to-Projected Revenue Ratio Nuwellis, Inc. NUWE|aethlonmedical.com (AEMD) - Market Cap to Future Revenue Ratio|ASXC - Price-to-Projected Revenue Ratio|Market Cap to Expected Sales Ratio Avinger Inc. AVGR|BioSig Technologies, Inc (BSGM) - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio Cutera Inc (CUTR)|Price-to-Projected Revenue Ratio Know Labs, Inc.|NARI: Forward Price to Sales|Forward P/S Multiple NVRO|Price-to-Projected Revenue Ratio RSLS (reshapelifesciences.com)|Forward P/S Multiple SILK (Silk Road Medical Inc.)
